Company news
Travere Therapeutics, Inc. news in 2026
Travere Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 12, 2026
Travere Therapeutics to Participate at Upcoming Investor Conferences
November 3, 2026
Travere Therapeutics Reports Third Quarter 2026 Financial Results
November 2, 2026
Travere Therapeutics to Report Third Quarter 2026 Financial Results
October 26, 2026
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
October 23, 2026
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2026
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
October 2, 2026
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
September 23, 2026
Travere Therapeutics Announces Planned Chief Executive Officer Transition
September 21, 2026
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
Travere Therapeutics Reports Second Quarter 2026 Financial Results
August 4, 2026
Travere Therapeutics to Report Second Quarter 2026 Financial Results
July 28, 2026
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
June 16, 2026
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
June 3, 2026
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
June 2, 2026
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
May 27, 2026
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 6, 2026
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 5, 2026
Travere Therapeutics Reports First Quarter 2026 Financial Results
May 3, 2026
Travere Therapeutics to Report First Quarter 2026 Financial Results
April 27, 2026
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
April 12, 2026
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
February 19, 2026
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
February 4, 2026
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
January 13, 2026
Travere Therapeutics Provides Corporate Update and 2026 Outlook
January 11, 2026
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Calls in 2026
- Travere Therapeutics (NASDAQ:TVTX) Q3 2026 Earnings Call
Nov 2, 2026
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q2 2026 Earnings Call
Aug 4, 2026
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q1 2026 Earnings Call
May 4, 2026
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q4 2025 Earnings Call
Feb 19, 2026
Transcript
Decks in 2026
- Q2 2026 Earnings Presentation
Earnings · 53 slides · Aug 4, 2026
- Corporate Update (June 2026)
Corporate update · 19 slides · Jun 2, 2026
- Q1 2026 Earnings Presentation
Earnings · 48 slides · May 4, 2026
- Corporate Update (April 2026)
Corporate update · 25 slides · Apr 13, 2026
- Q4 2025 Earnings Presentation
Earnings · 42 slides · Feb 19, 2026